
    
      This double-blind, placebo-controlled, multicenter, randomized Phase II study will consist of
      a 2-arm design, comparing E7080 + BSC (Arm 1) with placebo + BSC (Arm 2). Participants will
      be randomized in the ratio of 2:1 to receive either E7080 or placebo in a blinded manner.
    
  